]>
IRCT20200923048816N1 IRCT 2020-10-13 Esfahan University of Medical Sciences Investigating the effect of adding memantine to current therapies on the symptoms of post-traumatic stress disorder Investigating the effect of adding memantine to current therapies on the symptoms of post-traumatic stress disorder 2020-09-11 anticipated 30 Complete https://irct.ir/trial/51183 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients referred to a psychiatric clinic who meet the inclusion criteria are selected as double random blocks. The epidemiologist sets up a random number table, according to which the codes are assigned by hiding the code card in the thick envelopes (Concealed allocation), one of them to the memantine group with current treatment and the other to the placebo group with current treatment. Randomly assigned. These random double blocks continue until the data collection period is complete, Blinding description: To prevent bias and maintain blindness of the drugs in the intervention group and placebo, the patient prescribing the drug, the evaluator and the statistical consultant do not know the type of drug. Patients are treated up to 16 weeks after the intervention and re-examined at weeks 8 and 16. The psychiatrist who visits the patient and gives the packaged and coded drugs to the patient, the researcher who fills out the questionnaire, the researcher who enters the data into the software, and the epidemiologist who analyzes, the blind people in study. N/A Post-traumatic stress disorder. Intervention 1: Intervention group: Current treatment with memantine Patients in the first group or intervention group, in addition to the current treatment, are treated with the drug memantine with a starting dose of 5 mg per day and then increase the dose of the drug by 5 mg per week to a maximum dose of 20 mg per day. Intervention 2: Control group: Current treatment with placebo. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Fatemeh Fozveh
No 45, Bahar Ave., Hezar Jarib St.
Isfahan Iran (Islamic Republic of) 3145789674 +98 31 3786 1563 drfozveh.f@gmail.com Esfahan University of Medical Sciences scientific Fatemeh Fozveh
No 45, Bahar Ave., Hezar Jarib St.
Isfahan Iran (Islamic Republic of) 3145789674 +98 31 3786 1563 drfozveh.f@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Male and female patients with an age range of 19 to 65 years A case of battlefield PTSD diagnosed at least 12 months in advance according to DSM 5 criteria 19 years 65 years Both Patients with a history of dementia, schizophrenia, bipolar disorder, anxiety disorders, traumatic brain injury, and seizures according to DSM 5 criteria Patients with a history of alcohol and psychotropic drug use in the last month or the presence of addiction in the patient's history Patients need treatment with drugs that affect the glutamatergic system such as amantadine, dexamethasone or carbonic anhydrase inhibitors F43.1 Post-traumatic stress disorder (PTSD) Treatment - Drugs N/A Intervention group: Current treatment with memantine Patients in the first group or intervention group, in addition to the current treatment, are treated with the drug memantine with a starting dose of 5 mg per day and then increase the dose of the drug by 5 mg per week to a maximum dose of 20 mg per day. Control group: Current treatment with placebo Symptoms of post-traumatic stress disorder. Timepoint: At the beginning of the study, the eighth week and the sixteenth week. Method of measurement: Clinical Administered PTSD Scale. Esfahan University of Medical Sciences Approved 2020-09-23 Isfahan University of Medical Sciences Unit 2, Building 33, Shahid Alikhani Alley, Shahid Karimian Alley, Bagh Lake Street. Isfahan Isfehan Iran (Islamic Republic of)